BURLINGTON, Mass., March 12, 2013 /PRNewswire/ -- Decision Resources Group (DRG) invites pharmaceutical professionals to a one-day seminar of in-depth analysis covering key issues in the biologics and biosimilars market. The seminar, which will include presentations from prominent DRG analysts and an industry panel discussion, will be held May 2, 2013 at Hotel Solamar in San Diego, CA.
Andrew Merron, Ph.D., Director of the Biosimilars Advisory Service at Decision Resources Group, a recognized expert in the area of biologics and biosimilars, explained the timeliness of the seminar. "Though the first generation of biosimilar products experienced mixed commercial success in Europe, substantial commercial opportunity remains for future biosimilar agents across a wide variety of indications and new biologics continue to carve out niches and evolve current standards of care," said Dr. Merron.
Presentations at the seminar will address market trends and opportunities. Dr. Merron noted, "Sales of biologics have continued to grow globally despite increasing competition from biosimilars. However, developers of new branded biologics are now challenged to demonstrate clinical differentiation and developers of biosimilars are challenged to meet robust clinical comparability requirements."
This seminar is intended for pharmaceutical professionals involved in market research, business development and competitive intelligence. Attendees are invited to engage with analysts and peers with a post-event reception
For more information about the topics and speakers at the seminar go to http://www.competitivelandscapeseries.com/biologics-and-biosimilars/index.html
Media interested in further information or in attending the seminar should contact Roy Strunin at email@example.com or (781) 993-2515.
About the Competitive Landscape Seminar Series
The Competitive Landscape Seminar Series: Biologics and Biosimilars will be held on May 2, 2013. This high-value, one-day seminar has been developed specifically for biopharmaceutical market research executives as well as biologics and biosimilars product teams. Expert analysts from Decision Resources Group companies—Decision Resources and BioTrends Research Group—will share their latest research findings on key biologics and biosimilars trends.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Decision Resources Group
SOURCE Decision Resources Group